<DOC>
	<DOCNO>NCT03009734</DOCNO>
	<brief_summary>AntibioTx developping ATx201 topical product treatment skin infection , include infect atopic dermatitis .</brief_summary>
	<brief_title>Evaluation ATx201 Topical Antibiotic Agent</brief_title>
	<detailed_description>Treatment skin infection , include infect atopic dermatitis , plague inactivity resistance towards main topical antibiotic . Accordingly , infection either effectively treat harsh systemic antibiotic side effect need . Infections atopic dermatitis predominantly cause Staphylococcus aureus various specie Streptococcus . ATx201 potent antibiotic organism . ATx201 overcome current resistance problem methicillin resistant Staphylococcus aureus ( MRSA ) , vancomycin resistant enterococci ( VRE ) well resistance towards topical antibiotic . ATx201 also exhibit extraordinarily strong ability delay onset de novo resistance compare currently market antibiotic . The study combine Phase I/II study 36 healthy volunteer 40 patient . The primary objective demonstrate safety tolerability new topical formulation ATx201 healthy volunteer , population patient infect atopic dermatitis . Efficacy ATx201 eradicate S. aureus compare vehicle 4 7 day treatment evaluate . In Phase I study , three formulation ATx201 include respective Placebos apply healthy volunteer . One formulation advance Phase II , patient treat respective formulation Placebo .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>General inclusion criterion : Signed date informed consent obtain Age 18 70 year Male female Female subject childbearing potential must confirm pregnant negative urine pregnancy test prior trial treatment Female subject childbearing potential must willing use effective contraceptive trial entry completion Male subject must agree use adequate contraception duration trial Additional inclusion criterion Phase II study : Localized disease ( e.g . flexural eczema less symmetrical distribution arm ) two individual lesion cover area 10200 cm2 individual lesion investigator global assessment score 13 . Additional localized lesion area 10200 cm2 individual lesion investigator global assessment score 13 . Total localized disease exceed 20 % body surface area Colonization lesion S.aureus determine cultivation General exclusion criterion Clinically relevant abnormality laboratory testing , vital sign , ECG ( Phase I ) physical examination Presence skin condition ( scar , tattoo , â€¦ ) would interfere placement study medication History irritation topical product Current acute chronic disease unless consider clinically irrelevant Investigator Relevant history malignancy , renal , hepatic , cardiovascular , respiratory , gastrointestinal , musculoskeletal , skin ( particularly site drug application ) , haematological , endocrine neurological disease may interfere aim study Positive HIV serology evidence active hepatitis Ascertained presumptive hypersensitivity active principle and/or formulation ingredient study drug ( test , reference ) History drug alcohol abuse ( &gt; 2 drinks/day , define accord USDA Dietary Guidelines 2005 ) caffeine ( &gt; 5 cup coffee/tea/day ) tobacco abuse ( consumption 5 cigarettes/week ) abnormal special diet ( e.g . vegetarian diet ) Blood donation 6 week prior study plan within 6 week last blood withdrawal Subject consider unable unlikely ( per Investigator judgment ) comply safety PK profiling requirement ( followup visit ) Subjects pregnant ( determined positive pregnancy test screen visit ) lactate Participation another clinical trial investigational day within 4 week screen Additional exclusion criterion Phase I study : Regular use medication Use dermatological drug therapy arm within 14 day day 1 study Additional exclusion criterion Phase II study : Treatment antibiotic ( systemic topical ) within past 3 month study Treatment drug affect immune system within past 3 month study Treatment topical steroid calcineurin inhibitor 1 week study treatment period Treatment systemic steroid within past month study Use disinfectant soap within 1 week screen study treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>